---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-041735"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T04:18:34.235834+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD Q1 net loss narrows to $0.8M; strategic alternatives review ongoing

## Summary
- Net loss from continuing operations of $0.8M ($0.07/share) vs. $2.3M ($0.24/share) in Q1 2023.
- Gross license royalties of $1.2M under Mayne License Agreement; net royalties: $0.3M revenue and $0.3M other income.
- Operating expenses down 52.8% to $1.5M from $3.1M, driven by transition to royalty-based model.
- Cash and equivalents $4.3M at Mar 31, 2024; continues evaluating strategic alternatives including M&A or sale.

## SEC filing metadata
- accession: 0001213900-24-041735
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000121390024041735/0001213900-24-041735-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000121390024041735/ea0205779-8k_therape.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-041735
- JSON: https://secwatch.observer/filing/0001213900-24-041735.json
- Plain text: https://secwatch.observer/filing/0001213900-24-041735.txt

## Key facts
- Earnings Releases
  TherapeuticsMD, Inc. reported the first quarter ended March 31, 2024 results: revenue $0.3 million, net income $(0.8) million, EPS $(0.07) per basic and diluted common share.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $0.3 million
  - Net income: $(0.8) million
  - EPS: $(0.07) per basic and diluted common share
  - Result: reported results
  source text: in revenue, net and other income based on the proportion of the sales from each of our licensed products. Based on sales of our licensed products, the Company recognized $0.3 million in revenue, net, and approximately $0.3 million in other income in the three months ended March 31, 2024 related to net license royalties. Total Operating Expenses from
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000121390024041735/0001213900-24-041735-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.